(Q37254782)

19 August 2017

1 reference

title

Drug-induced hyperphagia: what can we learn from psychiatric medications? (English)

1 reference

19 August 2017

Gordon L Jensen

1

1 reference

19 August 2017

1 September 2008

1 reference

Journal of Parenteral and Enteral Nutrition

19 August 2017

1 reference

19 August 2017

32

1 reference

19 August 2017

5

1 reference

19 August 2017

578-581

1 reference

Antipsychotic-induced weight gain

19 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Medications associated with weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Psychiatric medication-induced obesity: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Genetic variants of the serotonin system and weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Clozapine in adolescent inpatients with acute mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Risperidone-associated weight gain in children and adolescents: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Atypical antipsychotics related metabolic syndrome in bipolar patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Imipramine and weight gain during the treatment of recurrent depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Bupropion for weight reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Olanzapine versus divalproex in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Do obese depressed patients respond to topiramate? A retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Topiramate and weight loss in patients with neurodevelopmental disabilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Valproate, weight gain and carbohydrate craving: a gender study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Lithium and body weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Lithium: clinical considerations in internal medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Early prediction of changes in weight during six weeks of treatment with antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Options for pharmacological management of obesity in patients treated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Psychiatric medication-induced obesity: treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Schizophrenia and weight management: a systematic review of interventions to control weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

Association of the G-2548A polymorphism in the 5′ region of the LEP gene with overweight

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0148607108321708

21 January 2018

Identifiers

DOI

10.1177/0148607108321708

1 reference

19 August 2017

1 reference

PubMed ID

18753398